Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for acute lymphoblastic leukemia following allogeneic stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

ESElizabeth J. Shpall

Discussion

Loading...

Member takes

Overview

Phase II trial shows promising safety and efficacy of venetoclax and azacitidine in acute lymphoblastic leukemia maintenance therapy post-transplant, indicating further study is warranted.

Key Points

  • Graft versus host disease was absent in all patients, with feasible use of venetoclax and azacitidine post-transplant.
  • Relapse-free survival was 77.8% at 1 and 2 years, with 6 patients discontinuing due to various factors during the trial.
  • Maintenance therapy involved 12 cycles of venetoclax and azacitidine with careful monitoring for toxicity and patient response.
  • Adverse events included grade 3–4 toxicities in 5 of 10 patients but no treatment-related infections were observed.

Cite This Study

Elizabeth J. Shpall (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e532https://doi.org/10.1182/blood-2025-2515
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation2025
  2. 2Venetolax plus azacitidine is effective maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with intermediate/high-risk Acute Myeloid Leukemia2025
  3. 3Phase II Results of ECOG-ACRIN EA9152: A multicenter study of liposomal vincristine (L-VCR) or vincristine sulfate (VCR) and venetoclax (VEN) in relapsed or refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL)2025
  4. 4A Phase 1B/2A study of weekly decitabine and venetoclax treatment as maintenance therapy in high-risk myeloid malignancy patients post allogeneic stem cell transplantation2025
  5. 5Azacitidine combined with Venetoclax for pre-emptive treatment of AML/MDS after allogeneic stem cell transplantation: A prospective phase II study2025